|
paxil voucher cr Icus in patients without epilepsy. Dose may be an important predisposing factor in the development of seizures paxil voucher cr, although seizures have been reported in patients taking daily doses of GABITRIL as low as 4mg day. In most cases paxil voucher cr, patients were using concomitant medications (antidepressants paxil voucher cr, antipsychotics paxil voucher cr, stimulants paxil voucher cr, narcotics) that are thought to lower the seizure threshold. Some seizures occurred near the time of a dose increase paxil voucher cr, even after periods of prior sable dosing. The GABITRIL dosing recommendations in current labeling for treatment of epilepsy were based on use in patients with partial seizures 12 years of age and older paxil voucher cr, most of whom were taking enzym paxil voucher cr.
paxil voucher cr E-inducing antiepileptic drugs (AEDs; e.g. paxil voucher cr, carbamazepine paxil voucher cr, phenytoin paxil voucher cr, primidone paxil voucher cr, and phenobarbital) which lower plasma levels of GABITRIL by inducing its metabolism. Use of GABITRIL without enzyme-inducing antiepileptic drugs result in blood levels about twice those attained in the studies on which current dosing recommendations are based (see DOSAGE AND ADMINISTRATION). Safety and effectiveness of GABITRIL have not been established for any indication other than as adjunctive therapy for partial seizures in adults and children 12 years and older. In nonepileptic patients who develop seizures while on GABITRIL treatment paxil voucher cr, GABITRIL should be discontinued and patients should be evaluated for an underlying seizure disorder. Seizures and status epilepticus are known to occur with GABITRIL overdosage (see OVERDOSAGE). Other changes to the label can be found in the PHARMACOKINETICS paxil voucher cr, ADVERSE REACTIONS paxil voucher cr, OVERDOSAGE paxil voucher cr, and DOSAGE AND ADMINISTRATION sections of the label. GABITRIL is approved for use only as adjunctive therapy in adults and children 12 years and older in the treatment of partial seizures. Because GABITRIL has not been systematically evaluated in adequate and well-controlled clinical trials for any other indication paxil voucher cr, its safety and effectiveness have not been established for any other use. Cephalon does not reco.
paxil voucher cr Ients should be evaluated for an underlying seizure disorder. Seizures and status epilepticus are known to occur with GABITRIL overdosage (see OVERDOSAGE). Other changes to the label can be found in the PHARMACOKINETICS paxil voucher cr, ADVERSE REACTIONS paxil voucher cr, OVERDOSAGE paxil voucher cr, and DOSAGE AND ADMINISTRATION sections of the label. GABITRIL is approved for use only as adjunctive therapy in adults and children 12 years and older in the treatment of partial seizures. Because GABITRIL has not been systematically evaluated in adequate and well-controlled clinical trials for any other indication paxil voucher cr, its safety and effectiveness have not been established for any other use. Cephalon does not recom.
paxil voucher cr 
paxil voucher cr | | | | | |
paxil voucher cr
|
